Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza immune globulin - Emergent BioSolutions

Drug Profile

Influenza immune globulin - Emergent BioSolutions

Alternative Names: Anti-influenza immune globulin intravenous (Human); FLU IGIV; Intravenous hyperimmune immunoglobulin; NP 025

Latest Information Update: 25 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergent BioSolutions
  • Developer Emergent BioSolutions; National Institute of Allergy and Infectious Diseases; University of Minnesota
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 17 Jun 2019 Emergent BioSolutions completes a phase II trial in Influenza A virus infections in USA, Canada, Spain and Puerto Rico (NCT03315104)
  • 17 Nov 2017 Emergent Biosciences initiates enrolment in a phase II trial for Influenza-A virus infection (IV) (NCT03315104)
  • 30 Oct 2017 Emergent Biosciences plans a phase II trial for Influenza-A virus infection (IV) in November 2017 (NCT03315104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top